CTRI/2024/02/063292尚未招募3 期
Assessment of Effectiveness of Empagliflozin in the Management of Anemia in Type 2 Diabetes Patients with Early Stage of Chronic Kidney Disease- A Prospective Randomised COntrol Study - NI
SRM Insitute of Science and Technology0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Estimated glomerular filtration rate 45 to 90 ml per minute .
- •Diabetic patients HbA1C greater than 6.5 percent
- •Patients with haemoglobin less than 13.0 g per dL in males.
- •Haemoglobin less than 12.0 g per dL in females.
排除标准
- •End Stage Renal Disease patients Stage 4
- •Patients with hereditary iron metabolism disorders.
- •Patients with Type 1 Diabetes mellitus.
- •Patients with pre-existing Urinary tract or Genital infections and patients who develop this complication during the study.
- •Patient with pyelonephritis.
- •Patients already taking diuretics.
- •Pregnant and Lactating women.
- •Treatment with any other investigational drug within the previous 30 days of inclusion in the study.
- •Any therapy or condition that would pose a risk to the patient or make it difficult to comply with study requirements.
- •Difficulty in Socio Culture Communication.
研究者
相似试验
招募中
3 期
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function testsIRCT20191209045671N3Semnan University of Medical Sciences60
尚未招募
3 期
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
已完成
3 期
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
招募中
4 期
The effect of empagliflozin in patients with idiopathic edemaIdiopathic edema.Edema, unspecifiedR60.9IRCT20230314057712N1Ahvaz University of Medical Sciences70
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90